ADE (chemotherapy)

{{Infobox medical intervention

| name = ADE

| synonym =

| image =

| caption =

| alt =

| pronounce =

| specialty = oncology

| synonyms =

| ICD10 =

| ICD9 =

| ICD9unlinked =

| CPT =

| MeshID =

| LOINC =

| other_codes =

| MedlinePlus =

| eMedicine =

}}

ADE is a chemotherapy regimen most often used as an induction or consolidation regimen in acute myelogenous leukemia, especially in poor-risk patients or those refractory to the standard first-line induction with standard "7+3" regimen or who are relapsed after the standard chemotherapy.

ADE regimen consists of three drugs:

1. Ara-C (cytarabine) - an antimetabolite;
2. Daunorubicin - an anthracycline antibiotic that is able to intercalate DNA and thus disrupt the cell division cycle, preventing mitosis;
3. Etoposide - a topoisomerase inhibitor.{{Cite web |url=http://www.bloodjournal.org/content/107/12/4614.abstract?sso-checked=true |title=Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial |access-date=2014-09-15 |archive-date=2015-09-23 |archive-url=https://web.archive.org/web/20150923193753/http://www.bloodjournal.org/content/107/12/4614.abstract?sso-checked=true |url-status=live }}